Synovial Fluid Collection for Arthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to collect and study synovial fluid, a liquid found in joints, from people with arthritis. Researchers seek to identify new markers that could help diagnose or predict the progression of arthritis and assess how treatments affect these markers. The trial suits individuals who experience significant joint swelling. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important advancements in arthritis care.
Why are researchers excited about this trial?
Unlike traditional treatments for arthritis that focus on managing symptoms or slowing disease progression, researchers are excited about this trial because it aims to create a synovial fluid bank from arthritic patients. This approach could offer new insights into the biological changes in arthritic joints and help develop more targeted therapies. By analyzing this fluid, scientists hope to discover unique biomarkers and pathways involved in arthritis, potentially leading to more precise and effective treatments tailored to individual patients.
Who Is on the Research Team?
Gilles Boire, MD, MSc
Principal Investigator
CHUS and Université de Sherbrooke
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Sample Collection
Collection of synovial fluid and paired sera from arthritic patients for biomarker evaluation
Preclinical Studies
Evaluation of novel biomarkers for diagnostic/prognostic values and regulation by therapeutic intervention
Follow-up
Participants are monitored for safety and effectiveness after sample collection and analysis
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
Gilles Boire
Lead Sponsor
Canadian Arthritis Network
Collaborator